...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of child and adolescent psychopharmacology >Predictors and Moderators of Antipsychotic-Related Weight Gain in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study
【24h】

Predictors and Moderators of Antipsychotic-Related Weight Gain in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study

机译：抗精神病药相关体重增加的预测因子和主持人治疗早熟精神分裂症谱系障碍研究中的研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Antipsychotic-related weight gain is a common clinically relevant side effect when treating psychotic disorders in pediatric populations, yet few predictors and no moderators of antipsychotic-related weight gain are known. Methods: The Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study randomized 119 youths (age 8-19 years) with schizophrenia or schizoaffective disorder to 8 weeks of antipsychotic treatment with molindone, risperidone, or olanzapine and assessed treatment response and side effects. In this secondary analysis, we used multivariable linear regression and receiver operating characteristic analysis to investigate predictors and moderators of weight change and percent weight change from baseline to week 8. Results: Treatment assignment was the most discriminant predictor of weight change [F(2, 66)=17.00, p0.001] and percent weight change [F(2, 66)=16.85, p0.001]. Mean weight gain was 0.74 (standard deviation 3.51) kg for molindone, 4.13 +/- 3.79kg for risperidone, and 7.29 +/- 3.44kg for olanzapine. After adjusting for treatment assignment, lower pretreatment hemoglobin A1C (HgbA1C) predicted more weight gain [F(1, 55)=4.71, p=0.03]. Diagnosis (schizoaffective vs. schizophrenia) moderated weight change [F(2, 63)=6.02, p=0.004] and percent weight change [F(2, 63)=5.26, p=0.008] such that schizoaffective diagnosis predicted larger weight gain for youths in the risperidone treatment arm. Age, sex, family income, baseline weight, and symptoms neither predicted nor moderated weight change or percent weight change. Conclusion: We identified prognostic subgroups and novel risk factors for antipsychotic-related weight gain. We confirmed that antipsychotic choice is extremely important for predicting future weight gain. We also found that younger age did not predict greater weight gain, in contrast to prior studies. Our findings require replication in an independent sample because we did not adjust for multiple comparisons to minimize false negatives. ClinicalTrials.gov Identifier: NCT00053703
机译：背景：抗精神病药相关的体重增加是一种常见的临床相关的副作用，当治疗儿科人群中的精神病疾病时，仍有很少的预测因子，并且没有抗精神病相关的重量增益的主持人。方法：治疗早盘性精神分裂症谱紊乱（TEOS）研究随机化119青年（8-19岁）与精神分裂症或血液化学障碍与莫林松，立妥酮或奥氮平的8周抗精神病药治疗，评估治疗响应和副作用。在该二级分析中，我们使用多变量的线性回归和接收器操作特征分析，以调查重量变化的预测因素和主持人，并从基线到第8周的重量变化百分比。结果：治疗分配是体重变化最判别的最判别预测因子[f（2， 66）= 17.00，P <0.001]和重量变化百分比[F（2,66）= 16.85，P <0.001]。 Molindone的平均体重增加为0.74（标准偏差3.51）kg，4.13 +/- 3.79kg，酮酮为7.29 +/- 3.44kg。调整治疗分配后，下预处理血红蛋白A1C（HGBA1C）预测更重量增益[F（1,55）= 4.71，P = 0.03]。诊断（SchizoAfferive Vs.Schizopheria）调节重量变化[F（2,63）= 6.02，p = 0.004]和重量变化百分比[F（2,63）= 5.26，p = 0.008]，使得SchizoAfferive诊断预测更大的体重增加对于Risperidone治疗臂中的年轻人。年龄，性别，家庭收入，基线重量和症状既没有预测也没有调节重量或重量变化百分比。结论：鉴定了对抗精神病相关权重增益的预后亚组和新危险因素。我们证实，抗精神病选择对于预测未来的体重增加非常重要。与先前的研究相比，我们还发现较年轻的年龄没有预测更大的体重增加。我们的研究结果需要在独立样本中复制，因为我们没有调整多种比较以最大限度地减少假底片。 ClinicalTrials.gov标识符：NCT00053703

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号